Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/40400
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hupperts, R | - |
dc.contributor.author | Gasperini, C | - |
dc.contributor.author | Lycke, J | - |
dc.contributor.author | Ziemssen, T | - |
dc.contributor.author | FEYS, Peter | - |
dc.contributor.author | Xiao, S | - |
dc.contributor.author | Acosta, C | - |
dc.contributor.author | Koster, T | - |
dc.contributor.author | Hobart, J | - |
dc.date.accessioned | 2023-06-14T09:54:13Z | - |
dc.date.available | 2023-06-14T09:54:13Z | - |
dc.date.issued | 2022 | - |
dc.date.submitted | 2023-06-08T10:54:34Z | - |
dc.identifier.citation | Therapeutic Advances in Neurological Disorders, 15 (Art N° 175628642210903) | - |
dc.identifier.uri | http://hdl.handle.net/1942/40400 | - |
dc.description.abstract | Background: MOBILE and ENHANCE were similarly designed randomized trials of walking-impaired adults with relapsing-remitting or progressive multiple sclerosis (MS) who received placebo or 10 mg prolonged-release (PR)-fampridine twice daily for 24 weeks. Both studies showed sustained and clinically meaningful improvement in broad measures of walking and balance over 24 weeks of PR-fampridine treatment. Objective: To evaluate the functional benefits and safety of PR-fampridine versus placebo using a post hoc integrated efficacy analysis of MOBILE and ENHANCE data. Methods: Data from the intention-to-treat (ITT) populations of MOBILE and ENHANCE studies were pooled in a post hoc analysis based on the following outcome measures: 12-item MS Walking Scale (MSWS-12), Timed Up and Go (TUG) speed, Berg Balance Scale (BBS), MS Impact Scale physical impact subscale (MSIS-29 PHYS), EQ-5D utility index score, visual analogue scale (VAS), and adverse events. The primary analysis was the proportion of people with MS (PwMS) with a mean improvement in MSWS-12 score (> 8 points) from baseline over 24 weeks. A subgroup analysis based on baseline characteristics was performed. Findings: In the ITT population (N = 765; PR-fampridine, n = 383; placebo, n = 382), a greater proportion of PR-fampridine-treated PwMS than placebo-treated PwMS achieved a clinically meaningful improvement in the MSWS-12 scale over 24 weeks (44.3% versus 33.0%; p < 0.001). PR-fampridine MSWS-12 responders demonstrated greater improvements from baseline in TUG speed, BBS score, MSIS-29 PHYS score, and EQ-5D utility index and VAS scores versus PR-fampridine MSWS-12 nonresponders and placebo. Subgroup analyses based on baseline characteristics showed consistency in the effects of PR-fampridine. Conclusion: The pooled analysis of MOBILE and ENHANCE confirms previous evidence that treatment with PR-fampridine results in clinically meaningful improvements in walking, mobility and balance, self-reported physical impact of MS, and quality of life and is effective across a broad range of PwMS. | - |
dc.language.iso | en | - |
dc.publisher | SAGE PUBLICATIONS LTD | - |
dc.subject.other | balance | - |
dc.subject.other | fampridine | - |
dc.subject.other | multiple sclerosis | - |
dc.subject.other | quality of life | - |
dc.subject.other | walking | - |
dc.title | Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE | - |
dc.type | Journal Contribution | - |
dc.identifier.volume | 15 | - |
local.bibliographicCitation.jcat | A1 | - |
local.publisher.place | 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
local.bibliographicCitation.artnr | 175628642210903 | - |
dc.identifier.doi | 10.1177/17562864221090398 | - |
dc.identifier.isi | 000799580800001 | - |
local.provider.type | Web of Science | - |
local.uhasselt.international | yes | - |
item.fullcitation | Hupperts, R; Gasperini, C; Lycke, J; Ziemssen, T; FEYS, Peter; Xiao, S; Acosta, C; Koster, T & Hobart, J (2022) Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE. In: Therapeutic Advances in Neurological Disorders, 15 (Art N° 175628642210903). | - |
item.validation | ecoom 2023 | - |
item.contributor | Hupperts, R | - |
item.contributor | Gasperini, C | - |
item.contributor | Lycke, J | - |
item.contributor | Ziemssen, T | - |
item.contributor | FEYS, Peter | - |
item.contributor | Xiao, S | - |
item.contributor | Acosta, C | - |
item.contributor | Koster, T | - |
item.contributor | Hobart, J | - |
item.fulltext | With Fulltext | - |
item.accessRights | Open Access | - |
crisitem.journal.issn | 1756-2856 | - |
crisitem.journal.eissn | 1756-2864 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hupperts-et-al-2022-efficacy-of-prolonged-release-fampridine-versus-placebo-on-walking-ability-dynamic-and-static.pdf | Published version | 5.45 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.